LM-008

LM-008 is a globally patented dual agonist of the glucagon-like peptide 1 receptor (GLP-1) and the glucagon receptor (GCGR), developed to address diabetes and obesity. Its mechanism targets both receptors to regulate blood glucose, appetite, and basal metabolism, aiming for improved glycemic control (reduction in HbA1c), lipid profile improvement (lowering triglycerides and total cholesterol), weight loss, and reduction of visceral fat. The drug is being developed by LeaderMed Group in collaboration with Combiphar for commercialization in Indonesia and other Asian markets with high prevalence of diabetes and obesity. Phase 3 clinical trials are expected to commence in late 2024, following positive results from a phase 2 trial conducted in the U.S., where it demonstrated superior cholesterol and triglyceride reduction compared to semaglutide. LM-008 is positioned as an alternative GLP-1-based therapy tailored for Asian populations[1][3][4][5].